
usd may pm et
summari develop manufactur market medic devic intervent medic
specialti three segment cardiovascular rhythm manag medsurg
price-to-earnings oper ep
risk assess reflect compani stabl
oper within competit area health care
industri high growth prospect howev
moder level debt net debt total capit
decemb continu success also
depend abil continu innov
commerci new innov -- easi task
jul ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
pm stock trade
prior widespread concern
expect sale grow
billion acceler growth
howev earli march
think could neg impact
sale growth basi point
elect procedur volum like
pressur year
one bsx anticip product
replac tavr experienc delay
 launch date origin date
allow
competitor captur bsx market
share debut lotu edg
increasingli see bsx structur heart
product portfolio includ tavr
key driver growth especi given
complementari product sentinel
expect bsx adjust oper margin
improv approxim basi point bp
success
expand margin past sever year
sustain product mix shift toward
higher-growth item bsx margin
climb year year
think share trade
ep estim
attract valu although
minor setback confid
signific upsid potenti
lotu edg tavr watchman flx
 acur valv
continu drive margin expans organ
revenu growth acceler believ
diversifi grow portfolio
product make top supplier hospit
expect mute activ
manag focus effort product
launch build capac acquisit
risk price recommend includ
increas competit price pressur
weak execut new product
target base
multipl ep
estim believ
warrant premium multipl rel
histor level compani
grow return capit driven chang
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview develop market minim invas medic devic
use broad rang intervent medic specialti offer product sale
seven core categori intervent cardiolog sale cardiac rhythm manag
endoscopi peripher intervent urolog pelvic health neuromodul
electrophysiolog seven core categori group three report segment
cardiovascular rhythm manag medsurg
cardiovascular segment includ intervent cardiolog peripher intervent
intervent cardiolog busi develop manufactur technolog diagnos treat
coronari arteri diseas cardiovascular disord includ structur heart condit product
includ drug-elut coronari stent system broad line product offer treat atherosclerosi
princip caus coronari arteri obstruct diseas devic structur heart therapi
watchman appendag closur acur aortic valv system brand peripher intervent
busi develop manufactur product diagnos treat peripher arteri diseas includ
broad line medic devic use percutan translumin angioplasti pta peripher
vascular diseas well product diagnos treat eas variou form cancer product
offer includ product stent balloon cathet wire atherectomi peripher
rhythm manag segment includ cardiac rhythm manag electrophysiolog
busi develop manufactur varieti implant devic monitor heart
deliv electr treat cardiac abnorm implant cardiovert defibril
pacemak current gener defibril reson famili devic avail
major market around world electrophysiolog busi develop manufactur
less-invas medic technolog use diagnosi treatment rate rhythm disord
heart includ broad portfolio therapeut diagnost cathet varieti equip
use electrophysiolog lab
medsurg segment includ endoscopi urolog pelvic health neuromodul
endoscopi busi develop manufactur devic diagnos treat broad rang
gastrointestin gi pulmonari condit innov less invas technolog urolog
pelvic health busi develop manufactur devic treat variou urolog pelvic condit
male femal anatomi includ kidney stone benign prostat hyperplasia bph erectil
dysfunct male incontin pelvic floor disord abnorm uterin bleed uterin fibroid
polyp neuromodul busi develop manufactur devic treat variou neurolog
movement disord manag chronic pain
competit landscap face signific competit across product line market
primari competitor includ plc cook medic well wide rang
medic devic compani sell singl limit number competit product particip
specif market segment like mani medic devic compani also face competit
non-med devic compani pharmaceut compani may offer altern therapi
diseas state could also treat use product
financi trend revenu grew billion compani five-year compound
annual growth rate compound-annual-growth-rate revenu meanwhil five-year compound-annual-growth-rate adjust ep
adjust ep vs spend larg amount research
develop year end decemb spent billion
revenu septemb elev net debt total capit ratio
leverag ratio net debt trailing-twelve-month ebitda
execut vice-president
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
under-valued usd
bullish sinc april technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
next month neg
recess concern although
medic devic sub-industri
histor defens recess resist
nonetheless expect near-term result
wors recent year despit neg
outlook think medic devic compani
fare much better compani
industri health care essenti
peopl expect
neg impact global procedur volum
procedur volum could quickli return
worst diseas impact pass
continu achiev robust organ growth
 mid-to-high single-digit revenu growth
driven new product grow
emerg market exposur howev expect
revenu neg impact
basi point result
mean anticip organ growth
low-single-digit
long run gener see posit
fundament trend medic devic
demand cost-effect value-bas health
care age popul rise outlay
result steadi flow
innov product revenu growth
 medic devic regul
mdr go effect may
follow vitro devic
regul ivdr goe effect
devic compani made much commentari
around introduct mdr reason
believ new regul could
neg impact industri exampl
juli submit letter
world trade organ request
mdr ivdr delay three year also
novemb european medic devic
trade associ critic slow
piecem implement new
accord evalu
billion valu prior
five-year averag deal total
billion industri debt level measur
net debt rel total capit appear
declin substanti follow
sever year increas think
industri could see increas deal
especi new ceo sever
major firm
prior concern expect
industri earn rise low-double-digit
percentag driven sale new product
command higher margin expect
industri earn rise mid-single-digit
percentag origin project
industri oper ebit margin
estim margin
think margin
like flat year-over-year
year date march health
equip sub-index declin
vs declin
composit index health
increas valu
base index
five-year market price perform may
note sector sub-industri inform base
past perform indic futur perform
reli upon
becton dickinson compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
adjust oper margin increas basi point yoy organ
basi medsurg segment grew rhythm neuro
cardiovascular emerg market continu area strength
sale grew organ follow growth prior-year period
spite concern rais fda earli year relat use drug
pacliataxel drug-elut stent de think eluvia de continu
growth driver expect fda provid updat guidanc
pm et cfra maintain strong buy opinion share boston
scientif maintain target
ep estim multipl exce rang
see strong potenti compani promis product portfolio
ep vs equal estim lift ep
sale increas organ billion
organ medsurg segment grew rhythm neuro
cardiovascular sale growth weaker expect
sever event includ fda concern relat paclitaxel
chemotherapi treatment fda halt sale transvagin mesh product
state-mand shutdown third-parti steril illinoi
despit minor setback maintain ep expect
forecast strong organ growth like
driven recent upcom key product launch lotu edg tavr
system approv fda yesterday /kevin huang cfa
pm et cfra keep strong buy opinion share boston scientif
lower price target base
ep estim fda warn physician last friday
march potenti increas long-term mortal
use paclitaxel-co balloon paclitaxel-elut stent treat
peripher arteri diseas forecast warn like
neg impact sale eluvia drug-elut stent coat
paclitaxel lower ep estim
ep maintain strong buy opinion share
compani still wide promis pipelin product /kevin
analyst research note compani news
pm et cfra keep strong buy opinion share boston scientif
keep price target base multipl
ep estim ep vs fell
short estim weaker-than-anticip oper margin
lower ep estim keep ep
organ basi net sale declin yoy led
declin rhythm neuro busi follow declin
cardiovascular growth medsurg respons
pandem made aggress cut variabl spend total
expens preserv critic invest exampl compani
shift temporarili four-day work week delay capit spend
plan posit view bsx enhanc liquid posit
achiev rework near-term coven push debt matur
expect bsx sale bounc back quickli patient schedul
delay procedur /kevin huang cfa
pm et cfra rais opinion share boston scientif strong
buy buy lower target price reflect
anticip impact earn lower ep estim
price target base forward price-to-earnings multipl
ep estim opinion recent stock market volatil
increas rel attract share
lift opinion share strong buy buy /kevin huang
pm et cfra maintain buy opinion share boston scientif
rais price
ep estim report ep vs
expect due tax benefit start ep estim
januari pre-announc organ sale growth
guidanc primarili due soft cardiac rhythm manag
busi anticip neg sale impact
million due novel coronaviru potenti impact procedur
volum china addit suppli chain disrupt result
provid weaker-than-expect organ growth guidanc vs
full-year guidanc find conserv look
ahead high expect structur heart busi
includ recent launch lotu edg soon-to-be-launch acur
exalt single-us duodenoscop watchman flx launch
 /kevin huang cfa
et cfra reiter buy opinion share boston scientif
corpor rais price target
base multipl ep estim believ
warrant premium multipl rel histor level
compani grow return capit ep vs met
expect organ sale growth acceler
larg due new product launch organ basi sale grew
cardiovascular segment follow growth medsurg
rhythm neuro mani analyst call rais concern
upcom data ischemia trial schedul present
novemb primari concern data unlik show
signific benefit intervent cardiolog approach vs optim
medic therapi alon patient stabl ischem heart diseas
believ neg outcom even worst-cas scenario highli
pm et cfra lower opinion share boston scientif buy
strong buy lift target base
multipl ep estim multipl
exce rang see strong potenti compani
product portfolio ep vs equal estim
rais ep lower ep
sale increas yoy organ billion
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd
repres total revenu estim fiscal
year analyst estim earn per
share grow usd
total
estimate estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
redistribut reproduct prohibit without prior written permiss copyright cfra
content includ rate credit-rel analys data valuat model softwar
applic output therefrom part thereof content may modifi
revers engin reproduc distribut form mean store
databas retriev system without prior written permiss cfra content shall
use unlaw unauthor purpos cfra third-parti provid
well director offic sharehold employe agent guarante
accuraci complet timeli avail content
past perform necessarili indic futur result
document may contain forward-look statement forecast forecast
reliabl indic futur perform
report intend constitut offer solicit buy sell
secur engag invest activ report inform purpos
recommend report made respect particular investor
type investor secur financi instrument strategi mention herein may
suitabl investor materi intend specif investor
take account investor particular invest object financi situat
need act recommend materi consid whether
suitabl particular circumst necessari seek profession advic
cfra may licens certain intellectu properti provid servic otherwis
busi relationship certain issuer secur subject cfra
research report includ exchange-trad invest whose invest object
substanti replic return proprietari index cfra case cfra
paid fee tie amount asset invest fund volum trade
activ fund invest fund may result cfra receiv compens
addit subscript fee compens servic render cfra
howev part cfra compens servic tie recommend
rate addit inform subject compani may avail upon request
cfra financi data provid global market intellig document contain
global industri classif standard gic develop and/or exclus
properti inc global market intellig gic servic mark
 global market intellig licens use cfra
disclaim notic
certain inform report provid global inc and/or affili
subsidiari collect global inform subject follow
disclaim notic copyright global market intellig affili
applic right reserv noth contain herein invest advic
refer particular invest secur credit rate observ
concern secur invest provid recommend buy
sell hold invest secur make invest decis may
contain inform obtain third parti includ rate credit rate
agenc reproduct distribut inform third parti content
form prohibit except prior written permiss global
relat third parti applic neither third parti provid guarante
accuraci complet timeli avail inform includ rate
respons error omiss neglig otherwis regardless
caus result obtain use inform content
includ rate credit rate statement opinion statement
fact recommend purchas hold sell secur address
suitabl secur suitabl secur invest purpos
reli invest advic
